July 31- August 1, 2020
We’ve invited 5 of the most influential Speakers from around the world to give inspirational talks and lead practical workshops.
Ceo The World Nano Foundation UK
Khaled Abbas Helmy Abdou
Chairman of Forensic Medicine & Toxicology Department Egypt
Principal investigator Portugal
Assistant Professor Kalasalingam University India
Head of Material Science and Nanotechnology Egypt
Pulsus Group is an internationally renowned peer-review publisher in scientific, technical, and medical journals established in the year 1984 with offices in Ontario, Canada and Hyderabad, India has acquired Andrew John Publishing and openaccessjournals.com to expand its Open Access Publishing through its 50+ journals in association with 20+ International medical and scientific societies.
Pulsus through its cmesociety.com is been very instrumental to provide an invaluable channel for scientists and researchers to exchange ideas and research by creating a forum for discussing the possibilities of future collaborations between universities, institutions, research bodies and organizations from different countries through international CME/CPD conferences and meetings.
Why to attend?
With members from around the world focused on learning about Nanomedicine and its advances; this is your best opportunity to reach the largest assemblage of participants from the Nanotechnology community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event.
The report is especially intended for entrepreneurs, investors, venture capitalists, and other readers with a need to know where the nanotechnology market is headed in the next 5 years. Other readers who should find the report particularly valuable include nanotechnology marketing executives and government officials associated with the National Nanotechnology Initiative and other state-level programs that promote the development of the nanotechnology industry. The report’s findings and conclusions should also be of interest to the broader nanotechnology community.
Nano Science and Nano Technology Researchers
Nano Science and Nano Technology Faculty
Nano Science and Nano Technology Associations and Societies
Global Nano Science and Nano Technology Companies
Nano Science and Nano Technology Investors
Exhibitors and Sponsors
Come be Part of it...!
The global nanomedicine market size was estimated at USD 138.8 billion in 2016. Technological advancements coupled with relevant applications in early disease diagnosis, preventive intervention, and prophylaxis of chronic as well as acute disorders is expected to bolster growth in this market. Nanotechnology involves the miniaturization of larger structures and chemicals at nanometric scale which has significantly revolutionized drug administration, thus influencing adoption of the technology through to 2025.
Expected developments in nanorobotics owing to the rise in funding from the government organizations is expected to induce potential to the market. Nanorobotics engineering projects that are attempting to target the cancer cells without affecting the surrounding tissues is anticipated to drive progress through to 2025.
North America dominated the nanomedicine market with revenue share of over 42% owing to presence of increasingly growing partnerships between enterprises operating herein and nanomedicine startup organizations. Furthermore, support from the government entities coupled with higher R&D spending is attributive for largest share of region in the industrial space.
Nanomedicine market, by region, 2016 (%)
However, Asia Pacific is expected to witness lucrative growth through to 2025 as a result of rise in number of research grants and increase in demand for prophylaxis of life-threatening diseases. Moreover, rise in the number of venture capital investors from developing economies of this region and increasing international research collaborations are anticipated to propel growth in nanotechnology-based healthcare industry.
Major players operating in this market are Combimatrix Corp, Ablynx NV, Abraxis Bioscience Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd, Arrowhead Research, GE Healthcare, Merck & Co. Inc., Pfizer Inc., and Nanosphere, Inc. These players are involved in gaining the U.S. FDA approvals in order to enhance the market presence.
For instance, in February 2017, company received approval from European Commission for its REVLIMID (lenalidomide) as monotherapy for treatment of patients with adult patients with multiple myeloma. This approval allows company to distribute its product in European countries, thereby enhancing company’s presence in Europe market.
· Application Outlook (Revenue, USD Billion; 2013 - 2025)
· Clinical Oncology
· Infectious diseases
· Clinical Cardiology
· Nanomolecule Type Outlook (Revenue, USD Billion; 2013 - 2025)
o Metal & Metal Oxide Nanoparticles
o By Type
o Gold Nanoparticles
o Silver Nanoparticles
o Iron Oxide Nanoparticles
o Alumina Nanoparticles
o Gadolinium Oxide Nanoparticles
o By Application
o In-vivo Imaging
o Targeted Drug Delivery
o Proton Therapy
o In-vitro assays
o Cell & Phantom Imaging
o Polymers & polymer drug conjugates
o Hydrogel nanoparticles
o Inorganic nanoparticles
· Regional Outlook (Revenue, USD Billion; 2013 - 2025)
· North America
· Asia Pacific
· Latin America
Middle East and Africa (MEA)
Track 1: Nanomedicine
Nano prescription is a part of medication that uses the Nanotechnology for the counteractive action and treatment of sickness in the human body. This developing control can possibly significantly change medicinal science. Nanomedicine blends the usage of nanoscale materials, for instance, biocompatible nanoparticles and nanorobots, for examination, conveyance, distinguishing or incitation purposes in a living structure. Current issues for nanomedicine incorporate understanding the issues related to lethality and environmental impact of nanoscale materials, Preparation of nano-prescriptions and its application. Research is being completed give a wide audit of magnetic nanoparticle, Silver nanoparticles, Gold nanoparticles explore with a special focus on the synthesis, functionalization and medicinal uses of these particles.
Track 2: Cancer And Nanotechnology
Nanotechnology can possibly build the selectivity and power of concoction, physical, and organic methodologies for inspiring disease cell demise while limiting collateral toxicity to non-malignant cells. Materials on the Nanoscale are progressively being focused on malignancy cells with extraordinary specificity through both active and passive targeting. Customary chemotherapeutics have some genuine reactions including the harm of the immune system and other organs with rapidly proliferating cells due to nonspecific targeting, absence of solvency, and failure to enter the center of the tumours bringing about weakened treatment with decreased dosage and with low survival rate. Nanotechnology can also provide sensitive and rapid detection of cancer and its related targets, enabling scientists to detect molecular changes even when they occur only in a small percentage of cells. Nanotechnology also has the ability to generate unique and highly effective therapeutic agents.
Track 3: Nanotechnology And Biomedical Applications
The utilization of innovation in medications and biomedical building are immense and ranges zones like embed and tissue designing, conclusion, Bio-Sensors, nano-tests, and therapeutic guide. There is another perspective for using innovation. Usually, the drug goes through the total body before they accomplish the infection impacted area. Using nanotechnology, the prescription can be engaged to a careful territory which would make the medicine significantly progressively effective and decline the chances of possible manifestations. Nanotechnology likewise discovers its application in dentistry, biosystems, respiratory maladies, Genetic nanomedicine and so on.
Track 4: Personalized Nanomedicine
Customized drug intends to individualize chemotherapeutic mediations based on ex vivo and in vivo information on patient-and sickness explicit qualities. By noninvasively envisioning how well picture guided nanomedicines-that is, sub-micrometer estimated tranquilize conveyance frameworks containing the medications and imaging administrators inside a singular plan and proposed to especially pass on medications particles to pathologic goals assemble at the objective site, patients inclined to respond to nanomedicine-based restorative mediations may be preselected. Likewise, by longitudinally seeing how well patients respond to nanomedicine-based restorative intercessions, sedate estimations and treatment conventions can be individualized and improved in the midst of advancement.
Track 5: Nanorobotics
Nanomedicine will be based on the ability to build Nanorobotics. In the future these Nanorobots could actually be programmed to repair specific diseased cells, functioning in a similar way to antibodies in our natural healing processes. The motivation for the new manipulation technology is the desire to enter the micro- and Nanoworld not only by viewing but also acting, altering micro- and nanosized objects. A new era on medicine are expected to happen in the coming years. Due to the advances in the field of Nanotechnology,Nanodevice manufacturing has been growing gradually. The elimination of bacterial infections in a patient within minutes, instead of using treatment with antibiotics over a period of weeks.
Track 6: Drug Delivery
Some smart drug delivery platform is based on neutral phospholipid Nanoliposomes. Where classic Classic liposomes modalities have had manufacturing problems involving sizing, uniformity, loading, storage, and enhancement compatibility, which can be overcome by employing true nanotechnology to build liposomes upon discrete self-assembling DNA scaffolds. The smart drug delivery system is used for delivering drugs to the host. Biological information detected by biological sensors is analyzed and the drug delivery system is actuated to deliver the drug based on the information. MEMS or NEMS technology based drug pumps, micro-pumps, micro-needles, micro-osmotic pumps, and nano-pumps are utilized for smarter drug delivery. One of the concerns these days about self-assembling nanotechnology is that it is so advanced beyond the current drug paradigmm that it becomes problematic from a regulatory point of view. While there is currently no drug treatment delivered directly into these types of cancers.
Track 7: Computational Studies in Nanoparticles
The computational studies in nanoparticles have demonstrated that there has been considerable progress in Nano and biotechnology in the last several years. However, several key challenges have also become apparent, including the need for a better understanding of nanoparticle behaviour in vivo and the development of more effective nanoparticle therapeutics. Computational efforts are becoming an important tool in addressing both of these challenges, as well as in generally facilitating and accelerating nanotechnology-based translational research. The Nanoinformatics has come out as a new research area that covers raw data management, analysis of the data derived from biomedical applications and simulation of nanoparticle interactions with biological systems depicting the integration of biology, nanotechnology and informatics to form the basis for computational Nanomedicine.
Track 8: Nanomedicine research
Nanomedicine has been developing rapidly in recent years, particularly in the development of novel Nano tools for medical diagnosis and treatment. For instance, a new trend is becoming prevalent in developing Nanosystems for simultaneous tumour diagnosis and therapy. A new terminology "Theranostics" has been frequently used and applied in pre-clinical research and trials. A Nanosystem can simultaneously achieve both cell targeted in vivo imaging and photothermal treatment of cancer. While achieving concurrent high spatial and temporal resolution of the lesions via cell targeting; special non-evasive treatments are implemented at the same time by various means, such as localized drug release hyperthermia, and photo-thermal therapy. Inspired by these challenging problems in biomedical fields, the development of the nanotechnologies will be the key in addressing some of the critical issues in medicine, especially in early cancer diagnosis and treatment.
Track 9: Precise Drug Delivery System
With the remarkable development of Nanotechnology in recent years, new drug delivery approaches based on the state-of-the-art nanotechnology have been receiving significant attention. Nanoparticles, an evolvement of nanotechnology, are increasingly considered as a potential candidate to carry therapeutic agents safely into a targeted compartment in an organ, particular tissue or cell. These particles are colloidal structures with a diameter less than 1,000 nm, and therefore can penetrate through diminutive capillaries into the cell’s internal machinery. This innovative delivery technique might be a promising technology to meet the current challenges in drug delivery. The different types of nanoparticles drug delivery systems under investigation and their prospective therapeutic applications, and also present a closer look at the advances, current challenges, and future direction of nanoparticles drug delivery systems.
Track 10: Polymer Nanoparticles
The use of nanoscale materials and processes to address human disease is perhaps the most promising, considering that most complex downstream symptoms of disease are initiated by molecular level phenomena. Nanomedicine is defined as biological and medical intervention at the nanometer scale for the treatment, diagnosis, and increased understanding of biology and disease. Tremendous advances in the area of polymer synthesis and self-assembly have given rise to a new toolbox of engineered nanosized delivery and diagnostic agents that permit systemic and local administration, circulation in the bloodstream, and uptake and diffusion at the cellular and subcellular level.
Track 11: Nano Drug System Characterization
Recent years have witnessed the rapid development of inorganic nanomaterials for medical applications. At present, nanomedicines-nanoparticles (NPs) destined for therapy or diagnosis purposes-can be found in a number of medical applications, including therapeutics and diagnosis agents .Pushing the limits of nanotechnology towards enhanced Nanomedicines will surely help to reduce side effects of traditional treatments and to achieve earlier diagnosis. The interplay between engineered nanomaterials and biological components is influenced by complex interactions which make predicting their biological fate and performance a nontrivial issue. We hope that both early-stage and experienced researchers will find it valuable for designing nanoparticles for enhanced bio-performance. Nanoemulsions have attracted great attention in research, dosage form design and pharmacotherapy. This is as a result of a number of attributes peculiar to nanoemulsions.
Track 12: Toxicology of Nanoparticles
Nanotechnology is a rapidly growing field having potential applications in many areas. Nanoparticles have been studied for cell toxicity, immunotoxicity, and genotoxicity. Tetrazolium-based assays such as MTT, MTS, and WST-1 are used to determine cell viability. Different types of cell cultures, including cancer cell lines have been employed as in vitro toxicity models. Considering the potential applications of NPs in many fields and the growing apprehensions of FDA about the toxic potential of Nanoproducts, it is the need of the hour to look for new internationally agreed, free of bias toxiological models by focusing more on in vivo studies. The rapid expansion of nanotechnology promises to have great benefits for society, yet there is increasing concern that human and environmental exposure to engineered nanomaterials may result in significant adverse effects. The system was developed for Nanotoxicity assessment at single and multiple cell levels which can measure and compare the microscopic and macroscopic effects of nanoparticles interaction with cells, without interference from neighbouring cells' cues and also overall integrative effects produced by nanoparticles and cell–cell communication.
Track 13: Emerging Nanomedicine
Currently, the treatment of HIV requires regular oral dosage of HIV drugs, and chronic oral dosing has significant complications that arise from the high pill burden experienced by many patients across populations with varying conditions leading to non-adherence to therapies. Recent evaluation of HIV patient groups have shown a willingness to switch to nanomedicine alternatives if benefits can be shown. Research efforts by the Liverpool team have focused on the development of new oral therapies, using Solid Drug Nanoparticles (SDN) technology which can improve drug absorption into the body, reducing both the dose and the cost per dose and enabling existing healthcare budgets to treat more patients.